Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Jul 17;5(7):e1331. doi: 10.1038/cddis.2014.286

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Macmillan Publishers Limited

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

PMC Copyright notice

Effect of anti-TRAIL administration on ischemic damage elicited by 100 min of transient middle cerebral occlusion followed by 24 hours of reperfusion. (a) In all, 200 μg/kg antiTRAIL, i.c.v. injected, induces neuroprotection in rats subjected to tMCAO followed by 24 h reperfusion. Infarct volume in rats subjected to tMCAO+Vehicle, tMCAO+20 μg/kg anti-TRAIL, tMCAO+200 μg/kg anti-TRAIL, and tMCAO+200 μg/kg scrambled anti-TRAIL. *P<0.05 versus all experimental groups. Each column represents the mean±S.E.M. (n=5–7) of the percentage of the infarct volume compared with the ipsilateral hemisphere. (b) In all, 200 μg/kg antiTRAIL injected i.c.v. ameliorates general and focal deficits in rats subjected to PC+tMCAO. *P<0.05 versus vehicle-treated animals